AXIM® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms
09 mai 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today announced...
AXIM® Biotechnologies, Inc. Nutraceutical Division Receives Purchase Order for 50,000 Boxes of the Company’s Proprietary CBD-Based Chewing Gum
23 avr. 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 23, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today...
AXIM® Biotechnologies, Inc. Announces Attendance and Presentation by Chief Technology Officer Lekhram Changoer at Kannaway® “Believe” National Convention
12 avr. 2019 09h30 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 12, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today...
AXIM® Biotech Enters Services Agreement With CRO to Begin Clinical Studies On Dronabinol and CBD Chewing Gums
09 avr. 2019 09h35 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC:AXIM), a world leader in cannabinoid research and development, today...
AXIM® Biotechnologies, Inc. Appoints Mauricio Javier Gatto-Bellora to Company’s Board of Directors
04 avr. 2019 11h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC:AXIM), a world leader in cannabinoid research and development, today...
Axim® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing Cannabinoids
19 mars 2019 11h59 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the...
AXIM® Biotechnologies Announces Successful Microencapsulation of Cannabinoids Into Proprietary Chewing Gum Delivery Mechanism for Clinical Trials
26 févr. 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the company...
AXIM® Biotechnologies Announces Significant Initial Purchase Order for Nutraceutical Product With Leading Direct Selling Company
12 févr. 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that the...
New U.S. Patent Issuance Granted to AXIM® Biotechnologies for Oral Care Composition Containing Cannabinoids
29 janv. 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Jan. 29, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that the...
AXIM® Biotechnologies Launches New Website and Management Presentation To Outline Strategic Business Initiatives
15 janv. 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Jan. 15, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the launch...